| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Microbial Metabolite
Sphingolipid metabolism; specific targets may include sphingomyelinase, glucocerebrosidase, and signaling molecules such as protein kinase C (PKC) and ceramide-activated protein phosphatases. Cerebrosides function as signaling molecules regulating cell proliferation, differentiation, and apoptosis. Also involved in immune modulation and may act as antigens. |
|---|---|
| ln Vitro |
No specific in vitro data available. Cerebrosides in general exhibit anti-tumor activity, inducing differentiation and apoptosis in cancer cell lines (HL-60 leukemia, MCF-7 breast). Immunomodulatory activities: activate NK cells and macrophages, enhance production of TNF-alpha, IL-12, IFN-gamma. Cerebroside D specifically has reported anti-tumor and immunomodulatory effects.
|
| ln Vivo |
No specific in vivo data available. Cerebrosides in general studied in animal models of cancer, showing anti-tumor effects in mice bearing sarcoma or leukemia xenografts. Also exhibit anti-inflammatory and neuroprotective effects in models of neurodegenerative diseases. Cerebroside D expected to have similar activities, but specific studies not reported.
|
| Enzyme Assay |
No specific protocols. For general sphingolipid studies: (1) Ceramide quantification: extract lipids from cells/tissues, separate by TLC or HPLC, quantify by MS. (2) Glucocerebrosidase activity: incubate lysates with 4-methylumbelliferyl-beta-D-glucopyranoside substrate, measure fluorescence at 360/446 nm.
|
| Cell Assay |
(1) For cellular studies: seed immune cells (NK cells, macrophages) or cancer cells in 96-well plates. (2) Treat with Cerebroside D (1-100 uM) for 24-72 h. (3) For NK activation: treat NK cells (1-50 uM) for 24 h, co-culture with target cancer cells (K562), measure cytotoxicity by LDH release. (4) For macrophage activation: treat RAW 264.7 cells (1-50 uM) for 6-24 h, measure TNF-alpha, IL-12, IL-6 by ELISA. (5) For apoptosis: treat cancer cells (5-100 uM) for 48 h, stain Annexin V-FITC/PI, flow cytometry.
|
| Animal Protocol |
(1) For anti-tumor: use BALB/c nude mice (20-25 g) bearing sarcoma, leukemia, or breast cancer xenografts. (2) Administer Cerebroside D IP (10-50 mg/kg) daily for 14-21 days. (3) Formulation: 10% DMSO/40% PEG300/5% Tween-80/45% saline for IP. (4) Monitor tumor volume and body weight twice weekly. (5) At endpoint, excise tumors, weigh, histology (H&E, IHC for Ki-67, cleaved caspase-3), TUNEL. (6) For immune modulation: collect spleens, isolate NK cells and measure cytotoxicity; measure serum cytokines by ELISA. (7) For neuroprotection: use MPTP-induced Parkinson's mouse model, administer Cerebroside D (10-30 mg/kg IP daily for 7-14 days), perform behavioral tests and measure dopaminergic neuron survival.
|
| ADME/Pharmacokinetics |
Lipid, poorly soluble in water. For in vitro, dissolve in DMSO (10-50 mM stock), dilute into medium with 0.1-0.5% BSA or FBS to aid solubilization. For in vivo, formulate in 10% DMSO/40% PEG300/5% Tween-80/45% saline for IP. Storage: powder at -20degC for 3 years, protect from light and moisture.
|
| Toxicity/Toxicokinetics |
In vitro: cerebrosides generally non-toxic at concentrations up to 100 uM in most cell types. In vivo: acute IP LD50 in mice typically >500 mg/kg. For research only.
|
| References | |
| Additional Infomation |
Cerebroside D has been reported to be found in Albatrellus ellisii, Cortinarius lucorum, and other organisms with available data.
Cerebroside D is a glycosphingolipid isolated from natural sources (fungi, mushrooms). Cerebrosides are important structural components of cell membranes, especially in nervous system, involved in cell-cell recognition, signaling, and myelin stability. Function as second messengers in cell growth, differentiation, and apoptosis pathways. Studied for potential anti-tumor, immunomodulatory, and neuroprotective activities. Not FDA-approved; strictly for research in sphingolipid biology, cancer immunology, and neurodegenerative diseases. |
| Molecular Formula |
C43H81NO9
|
|---|---|
| Molecular Weight |
756.105
|
| Exact Mass |
755.591
|
| CAS # |
113773-89-0
|
| PubChem CID |
10147101
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
11.3
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
34
|
| Heavy Atom Count |
53
|
| Complexity |
931
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCCCCCCCCCCCCCC(O)C(=O)NC(COC1OC(CO)C(O)C(O)C1O)C(O)\C=C\CC\C=C(/C)CCCCCCCCC
|
| InChi Key |
RIZIAUKTHDLMQX-NSWGQNMASA-N
|
| InChi Code |
InChI=1S/C43H81NO9/c1-4-6-8-10-12-13-14-15-16-17-18-20-22-26-31-37(47)42(51)44-35(33-52-43-41(50)40(49)39(48)38(32-45)53-43)36(46)30-27-23-25-29-34(3)28-24-21-19-11-9-7-5-2/h27,29-30,35-41,43,45-50H,4-26,28,31-33H2,1-3H3,(H,44,51)/b30-27+,34-29+/t35-,36+,37+,38+,39+,40-,41+,43+/m0/s1
|
| Chemical Name |
(2R)-2-hydroxy-N-[(2S,3R,4E,8E)-3-hydroxy-9-methyl-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]octadecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3226 mL | 6.6128 mL | 13.2256 mL | |
| 5 mM | 0.2645 mL | 1.3226 mL | 2.6451 mL | |
| 10 mM | 0.1323 mL | 0.6613 mL | 1.3226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
